Seres Therapeutics, Inc. MCRB
3.52
(0.10)
(2.76%)
as of 25 Sep
- Market cap
- $36.0M
- P/E
- 0.0×
Follow MCRB
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (66.57%) | (121.87%) | 19.64% | 15.95% |
+8 more TTM periods Free account |
|
| (18.31%) | (33.29%) | 4.10% | 3.35% | ||
ROIC |
(277.30%) | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(79.90%) | (242.41%) | 15.11% | 14.32% | |
Average Days of Receivables |
4,899.10 | 55.91 | 128.11 | 2.22 | |
Free Cash Flow per Share |
(5.28) | (4.40) | 0.12 | (2.67) | |
Free Cash Flow |
(51.25) | (42.15) | 1.08 | (23.37) | |
Capital Expenditures |
0.01 | — | (0.04) | (0.31) | |
Piotroski F-Score |
3.00 | 3.00 | 4.00 | 5.00 | |
| Other line items | |||||
Cash ROIC |
(102.25%) | (74.83%) | 1.24% | (25.24%) | |
Accounts Receivable Turnover |
0.14 | 1.02 | 1.14 | 13.16 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
2,476.69% | 3,315.84% | 3,330.62% | 39.38% | |
Selling, General and Administrative Expense of Revenue |
1,707.17% | 2,323.34% | 2,658.25% | 34.57% | |
Share Based Compensation of Revenue |
487.84% | 643.46% | 735.91% | 8.95% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
2.28 | 0.90 | 0.20 | (4.27) | |
Depreciation/Fixed assets |
0.59 | 0.56 | 0.54 | 0.50 | |
Capex/Depreciation |
0.00 | 0.00 | (0.01) | (0.07) | |
Revenue per Share |
0.19 | 0.16 | 0.17 | 14.56 | |
Operating CF per Share |
(5.28) | (4.40) | 0.13 | (2.63) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.04) | |
Capex to Sales |
0.00 | 0.00 | 0.03 | 0.00 | |
Net Profit Margin |
(1,192.94%) | (3,083.43%) | 386.69% | 4.23% |
Columns are period end dates